However, the strength of TRIUMPH-4 data and the commercial incentive for Eli Lilly make significant delays unlikely barring an unexpected safety finding
What to Expect in Month 1 Appetite changes: Noticeable suppression begins week 3-4 for most Mild nausea: 40% experience some nausea, usually mild Injection site reactions: Redness, itching, or mild pain at injection site (14% of patients) Fatigue: Some patients report low energy as body adjusts Bowel changes: Either constipation or looser stools as medication affects gut motility 4 Essential Strategies for Month 1 1
These medications have genuinely transformed how we manage type-2 diabetes and weight loss, and many patients are seeing remarkable results
JX is the guarantor of this work and had full access to all the data in the study and also takes responsibility for the integrity of the data
Anxiety on tirzepatide and muscle pain with tirzepatide have also been reported, though these are less common
In a statement, Scott Brunner, CEO of the Alliance for Pharmacy Compounding (APC), called the report concerning but incomplete
